Esco Group is a Singapore based life sciences tools manufacturer with sales in over 100 countries.
Esco Group has a unique track record of consistent (mainly organic) growth in the teens over a 10+ year period, driven by the ability to identify and enter attractive market niches globally, without the benefit of having a large domestic market.
Esco Group now has subsidiaries in the US, Europe (UK, Italy, Denmark), across the Asia-Pacific region (China, Japan, India, Singapore and major ASEAN countries), Middle East and Africa.
We differentiate ourselves by adding operational value in global distribution and scale up, leveraging on the capabilities of the Esco Group. We are more than a financial investor, we are true strategic partners.
Our founders have extensive hands-on experience in small company / start up environments having successfully developed and launched multiple product lines for the global life sciences tools market.
We know that investments in the life sciences tools and medical technology industry do not pay off overnight. We do not seek control from day one and we are an evergreen fund.
We simply enjoy doing what we have done all these years -- help take innovations which can make our human world healthier, safer and better to the global market.
We live in an age where the vast majority of humanity has all basic needs and most wants satisfied. At such a juncture, man wants to live longer and healthier.
The fact that biology is unpredictable and so much is still unknown (yet so much knowledge is being uncovered now) means that there will be great things to be achieved for those willing to play at the cutting edge of medicine, science and risk taking entrepreneurship in the 21st century.
The health care system as we know it today is in need of reform. Pharma, providers and physicians profit from illness. In the US, health care costs are runaway with mediocre outcomes. Too much is spent on end of life care (especially in the US).
With increased affluence and empowerment of women, fertility rates have declined globally. Many countries are aging and the health care burden will soon be too much to bear in both advanced and even in emerging economies. Governments will need to keep their citizens working productively for longer.
The future of health care lies in precision and prevention. The technologies enabling this are increasingly available, but they are just beginning to be integrated holistically in a manner which creates lasting value for all stakeholders. Early detection and diagnosis will become more important than ever, as prevention is obviously better than cure. Of course, the world will always need new cures, but the bar must be set higher for patient stratification, and cost effectiveness.
Esco Ventures is investing in and incubating technologies addressing unmet needs with the potential for outsized impacts to health care globally which reduce costs, improve the patient experience and improve patient outcomes. We invite like minded partners, scientists, clinicians, entrepreneurs, investors and other stakeholders to join us on this journey.
Group President & CEO
Esco Group of Companies
Changing the world through enabling technologies which improve outcomes, reduce costs and enhance the patient experience.
Founder & Managing Partner
Entrepreneur, CEO, Product Developer, Investor
Young Singaporean entrepreneur with experience in the life sciences tools / medtech industry, global work experience and contacts, proven business management and early stage investment track record.
Nir has extensive experience in multiple startup companies developing therapeutics and diagnostics. Until recently Nir was Head of R&D for Acumen research laboratories involved in a clinically relevant diagnostic tool for Sepsis. Nir previously served as a project manager at VIDAC-Pharma, a startup company developing novel small molecules for the treatment of cancer based on a unique mode of action.
Throughout his work, Nir led the R&D of pre-clinical phase of development of API for the treatment of non-melanoma skin cancer. He obtained his PhD degree from Ben-Gurion University in Israel.
Debjit, is a Chemist by training with extensive experience in medical technologies. Prior to Esco Ventures Debjit worked as a contract research analyst for a Biotech equity research firm Life Science Advisors in New York and as a partner of a Biotech investment club associated with Memorial Sloan Kettering Cancer Centre.
Debjit obtained his PhD in Chemistry from University of North Carolina at Chapel Hill (2011) where he developed chemoselective liposome fusion strategy for generation of three dimensional tissue structures. He has done postdoctoral research at Columbia University (NY), Institute for Stem Cell Biology and Regenerative Medicine (Bangalore) and at Genome Institute of Singapore where his research work was focused on developing a three dimensional high throughput screening platform for oral cancer drugs.
Dan is a biophysicist with expertise in imaging and sensing technologies. Prior to joining Esco Ventures, he led the development of novel methods for high resolution cathodoluminescence microscopy. At Harvard, Dan’s postdoctoral research focused on photonic and nanoparticle based technologies for biosensing. For his dissertation research at Harvard Medical School, Dan developed a fluorescence based platform to study a key step in viral infection. Dan obtained his PhD from Harvard University.
Assistant General Manager, Esco Ventures Chinaa
Tiger has extensive research experience in protein and molecular biology. His involvement in many life science companies for several years helped him gain skills in market research, project selection and execution, technical support, after sales service management, and business development, as well as knowledge of China FDA Medical Devices Registration. As part of Esco Ventures China, Tiger manages the registration and commercialization of different new projects addressing unmet needs. Tiger obtained his master’s degree from Shanxi University in China.
Senior Program Specialist, Esco Ventures China
Jiang Tao obtained his doctoral degree from the China Agricultural University in 2013. He worked on his postdoctoral research in the Chinese Academy of Medical Sciences where he gained an extensive research experience in molecular biology and cell engineering. Being part of the Esco Ventures China, Jiang Tao handles market research and analysis for life science projects.
We are proud to support companies that are creating tremendous amounts of value in their respective industries.
AT Medical Ltd. develops, manufactures and sells state of the art medical device technology.
Check-Cap is a clinical stage medical diagnostics company leading the development of the first ingestible imaging capsule that utilizes low-dose X-rays for CRC screening.
Hummingbird Bioscience focuses on the discovery and early development of oncology drugs, from pre-clinical target validation through to proof-of-concept (Phase II clinical trials).
Explore our latest news stories, read our investors' insights, and discover what our portfolio companies have recently accomplished here.
The distinguished Council of Presidential Advisors visited Esco Ventures Incubator Facility in Ayer Rajah Crescent, Singapored on the 22nd of July 2016.
The investment arm of Esco Group is dedicated to nurture promising
early-stage startups with novel innovations and technologies in the...
Esco Group, a Singapore-based life sciences tools and medical devices manufacturer, announced
the establishment of Esco Ventures...
Locations: San Francisco Bay Area, China, and Singapore
Esco, a leading Singapore based life sciences tools, medical devices and diagnostics global company is seeking a PhD level Research Analyst for its Corporate Ventures arm.
Interested candidates please submit a cover letter and CV to firstname.lastname@example.org.
Esco is a Singapore headquartered life sciences tools and medical devices group with manufacturing, R&D and direct sales across the U.S., Europe and Asia. Esco is led by XQ Lin, a young Singaporean entrepreneur and Wharton graduate, who has transformed the group's business from a small company to a global enterprise with over 700 employees.
Interested candidates please submit a cover letter and CV to XQ.email@example.com.